The project entitled:

"Novel approaches for diabetes management by combination of inhibition of DYRK1A kinase and stem cells application."

funded by National Agency for Scientific Exchange, Poland between 2019 and 2023.

The worldwide incidence of Diabetes, which is directly associated with the rapid rise of obesity, cancer, cardiovascular and Alzheimer's disease, has been rising exponentially for the past few decades and still without a cure, but only with temporary treatments. The international collaborative research project designed by our laboratory will allow the advancement of science towards an efficient therapy against this devastating disease. It will be achieved by combining advanced fields from protein crystallography and chemical synthesis for the final development of a dual specificity tyrosine-regulated kinase-1a (DYRK1A) inhibitors to restore beta-cell function in the diabetic pancreas; patient-derived induced pluripotent stem cells (iPSCs) to regenerate the pancreatic beta-cell mass; and nanodelivery systems to enhance the delivery and functionality of both drug and cells, all synchronized for an effective and personalized cure for Diabetes.